

In the Claims

A complete set of pending claims is presented below.

1. (Previously presented) A percutaneous absorption adhesive preparation comprising a base drug salt and an organic acid salt, wherein said organic acid salt is in the form of powder having a mean diameter of 0.1-100 μm , and said drug forms an ion-pair with the organic acid salt.
2. (Previously presented) The percutaneous absorption adhesive preparation according to claim 1, wherein the mean diameter of the organic acid salt is 0.1-10 μm .
3. (Previously presented) The percutaneous absorption adhesive preparation according to claim 1 comprising the organic acid salt of 0.01-15% by weight.
4. (Previously presented) The percutaneous absorption adhesive preparation according to claim 1 comprising the base drug salt of 0.1-20% by weight.
5. (Previously presented) The percutaneous absorption adhesive preparation according to claim 1, wherein the organic acid salt is an acetic acid salt.
6. (Previously presented) The percutaneous absorption adhesive preparation according to claim 5, wherein the organic acid salt is sodium acetate.
7. (Previously presented) The percutaneous absorption adhesive preparation according to claim 2 comprising the organic acid salt of 0.01-15% by weight.
8. (Previously presented) The percutaneous absorption adhesive preparation according to claim 2 comprising the base drug salt of 0.1-20% by weight.
9. (Previously presented) The percutaneous absorption adhesive preparation according to claim 2, wherein the organic acid salt is an acetic acid salt.

10. (Previously presented) The percutaneous absorption adhesive preparation according to claim 9, wherein the organic acid salt is sodium acetate.
11. (Previously presented) The percutaneous absorption adhesive preparation according to claim 3, wherein the organic acid salt is an acetic acid salt.
12. (Previously presented) The percutaneous absorption adhesive preparation according to claim 11, wherein the organic acid salt is sodium acetate.